{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T11:37:23Z","timestamp":1770723443645,"version":"3.49.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s40265-016-0584-1","type":"journal-article","created":{"date-parts":[[2016,5,4]],"date-time":"2016-05-04T17:14:00Z","timestamp":1462382040000},"page":"879-887","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Gabapentin Enacarbil: A Review in Restless Legs Syndrome"],"prefix":"10.1007","volume":"76","author":[{"given":"Esther S.","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma D.","family":"Deeks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,5,4]]},"reference":[{"issue":"8","key":"584_CR1","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.sleep.2014.03.025","volume":"15","author":"RP Allen","year":"2014","unstructured":"Allen RP, Picchietti DL, Garcia-Borreguero D, et al. Restless legs syndrome\/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria-history, rationale, description, and significance. Sleep Med. 2014;15(8):860\u201373.","journal-title":"Sleep Med."},{"issue":"89","key":"584_CR2","first-page":"402","volume":"2013","author":"K Nagandla","year":"1053","unstructured":"Nagandla K, De S. Restless legs syndrome: pathophysiology and modern management. Postgrad Med J. 1053;2013(89):402\u201310.","journal-title":"Postgrad Med J."},{"issue":"4","key":"584_CR3","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.smrv.2011.05.002","volume":"16","author":"MM Ohayon","year":"2012","unstructured":"Ohayon MM, O\u2019Hara R, Vitiello MV. Epidemiology of restless legs syndrome: a synthesis of the literature. Sleep Med Rev. 2012;16(4):283\u201395.","journal-title":"Sleep Med Rev."},{"issue":"1","key":"584_CR4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s13311-013-0247-9","volume":"11","author":"CL Comella","year":"2014","unstructured":"Comella CL. Treatment of restless legs syndrome. NeuroTherapeutics. 2014;11(1):177\u201387.","journal-title":"NeuroTherapeutics."},{"issue":"11","key":"584_CR5","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s11940-014-0317-2","volume":"16","author":"WG Ondo","year":"2014","unstructured":"Ondo WG. Restless legs syndrome: pathophysiology and treatment. Curr Treat Options Neurol. 2014;16(11):317.","journal-title":"Curr Treat Options Neurol."},{"issue":"8","key":"584_CR6","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/nrneurol.2015.122","volume":"11","author":"C Trenkwalder","year":"2015","unstructured":"Trenkwalder C, Winkelmann J, Inoue Y, et al. Restless legs syndrome-current therapies and management of augmentation. Nat Rev Neurol. 2015;11(8):434\u201345.","journal-title":"Nat Rev Neurol."},{"key":"584_CR7","doi-asserted-by":"crossref","unstructured":"Rios Romenets S, Postuma RB. Treatment of restless legs syndrome. Curr Treat Options Neurol. 2013;15(4):396\u2013409.","DOI":"10.1007\/s11940-013-0241-x"},{"key":"584_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.sleep.2016.01.017","volume":"21","author":"D Garcia-Borreguero","year":"2016","unstructured":"Garcia-Borreguero D, Silber MH, Winkelman JW, et al. Guidelines for the first-line treatment of restless legs syndrome\/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Med. 2016;21:1\u201311.","journal-title":"Sleep Med."},{"issue":"12","key":"584_CR9","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s40263-012-0020-3","volume":"26","author":"LJ Scott","year":"2012","unstructured":"Scott LJ. Gabapentin enacarbil: in patients with restless legs syndrome. CNS Drugs. 2012;26(12):1073\u201383.","journal-title":"CNS Drugs."},{"key":"584_CR10","unstructured":"US FDA. Horizant (gabapentin enacarbil) extended-release tablets: US prescribing information. 2013. http:\/\/www.fda.gov . Accessed 26 Apr 2016."},{"issue":"1","key":"584_CR11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/0091270012439209","volume":"53","author":"R Lal","year":"2013","unstructured":"Lal R, Sukbuntherng J, Luo W, et al. Population pharmacokinetics and pharmacodynamics of gabapentin after administration of gabapentin enacarbil. J Clin Pharmacol. 2013;53(1):29\u201340.","journal-title":"J Clin Pharmacol."},{"issue":"12","key":"584_CR12","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/j.clinthera.2013.10.011","volume":"35","author":"M Davy","year":"2013","unstructured":"Davy M, Upward J, Arumugham T, et al. Cardiac repolarization with gabapentin enacarbil in a randomized, double-blind, placebo- and active-controlled, crossover thorough QT\/QTc study in healthy adults. Clin Ther. 2013;35(12):1964\u201374.","journal-title":"Clin Ther."},{"key":"584_CR13","doi-asserted-by":"crossref","unstructured":"Chen D, Lal R, Zomorodi K, et al. Evaluation of gabapentin enacarbil on cardiac repolarization: a randomized, double-blind, placebo- and active-controlled, crossover thorough QT\/QTc study in healthy adults. Clin Ther. 2012;34(2):351\u201362.e3.","DOI":"10.1016\/j.clinthera.2012.01.002"},{"issue":"8","key":"584_CR14","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/j.clinthera.2009.07.026","volume":"31","author":"R Lal","year":"2009","unstructured":"Lal R, Sukbuntherng J, Luo W, et al. Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers. Clin Ther. 2009;31(8):1776\u201386.","journal-title":"Clin Ther."},{"issue":"1","key":"584_CR15","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1124\/jpet.104.067934","volume":"311","author":"KC Cundy","year":"2004","unstructured":"Cundy KC, Branch R, Chernov-Rogan T, et al. XP13512 [(\u00b1)-1-([(\u03b1-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J Pharmacol Exp Ther. 2004;311(1):315\u201323.","journal-title":"J Pharmacol Exp Ther."},{"issue":"12","key":"584_CR16","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1177\/0091270008322909","volume":"48","author":"KC Cundy","year":"2008","unstructured":"Cundy KC, Sastry S, Luo W, et al. Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. J Clin Pharmacol. 2008;48(12):1378\u201388.","journal-title":"J Clin Pharmacol."},{"issue":"2","key":"584_CR17","doi-asserted-by":"crossref","first-page":"109","DOI":"10.5414\/CPP49109","volume":"49","author":"R Lal","year":"2011","unstructured":"Lal R, Sukbuntherng J, Ho J, et al. A phase I, single-dose study of the disposition of 14C-radiolabeled gabapentin enacarbil in healthy male volunteers. Int J Clin Pharmacol Ther. 2011;49(2):109\u201315.","journal-title":"Int J Clin Pharmacol Ther."},{"issue":"5","key":"584_CR18","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1365-2125.2010.03616.x","volume":"69","author":"R Lal","year":"2010","unstructured":"Lal R, Sukbuntherng J, Luo W, et al. Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidine. Br J Clin Pharmacol. 2010;69(5):498\u2013507.","journal-title":"Br J Clin Pharmacol."},{"issue":"2","key":"584_CR19","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.clinthera.2014.10.015","volume":"37","author":"C Chen","year":"2015","unstructured":"Chen C, Upward J, Arumugham T, et al. Gabapentin enacarbil and morphine administered in combination versus alone: a double-blind, randomized, pharmacokinetic, and tolerability comparison. Clin Ther. 2015;37(2):349\u201357.","journal-title":"Clin Ther."},{"issue":"4","key":"584_CR20","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/WNF.0b013e318259eac8","volume":"35","author":"R Lal","year":"2012","unstructured":"Lal R, Ellenbogen A, Chen D, et al. A randomized, double-blind, placebo-controlled, dose-response study to assess the pharmacokinetics, efficacy, and safety of gabapentin enacarbil in subjects with restless legs syndrome. Clin Neuropharmacol. 2012;35(4):165\u201373.","journal-title":"Clin Neuropharmacol."},{"issue":"1","key":"584_CR21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1185\/03007995.2012.746217","volume":"29","author":"Y Inoue","year":"2013","unstructured":"Inoue Y, Hirata K, Uchimura N, et al. Gabapentin enacarbil in Japanese patients with restless legs syndrome: a 12-week, randomized, double-blind, placebo-controlled, parallel-group study. Curr Med Res Opin. 2013;29(1):13\u201321.","journal-title":"Curr Med Res Opin."},{"issue":"3","key":"584_CR22","doi-asserted-by":"crossref","first-page":"282","DOI":"10.5664\/JCSM.1074","volume":"7","author":"DO Lee","year":"2011","unstructured":"Lee DO, Ziman RB, Perkins AT, et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome. J Clin Sleep Med. 2011;7(3):282\u201392.","journal-title":"J Clin Sleep Med."},{"issue":"11","key":"584_CR23","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1002\/mds.23771","volume":"26","author":"JW Winkelman","year":"2011","unstructured":"Winkelman JW, Bogan RK, Schmidt MH, et al. Randomized polysomnography study of gabapentin enacarbil in subjects with restless legs syndrome. Mov Disord. 2011;26(11):2065\u201372.","journal-title":"Mov Disord."},{"issue":"5","key":"584_CR24","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1212\/01.wnl.0000341770.91926.cc","volume":"72","author":"CA Kushida","year":"2009","unstructured":"Kushida CA, Becker PM, Ellenbogen AL, et al. Randomized, double-blind, placebo-controlled study of XP13512\/GSK1838262 in patients with RLS. Neurology. 2009;72(5):439\u201346.","journal-title":"Neurology."},{"key":"584_CR25","unstructured":"GlaxoSmithKline. Result summary: study 114025. 2014. http:\/\/www.gsk-clinicalstudyregister.com\/files2\/114025-Clinical-Study-Result-Summary.pdf . Accessed 26 Apr 2016."},{"key":"584_CR26","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.sleep.2015.11.002","volume":"19","author":"DO Lee","year":"2015","unstructured":"Lee DO, Buchfuhrer MJ, Garcia-Borreguero D, et al. Efficacy of gabapentin enacarbil in adult patients with severe primary restless legs syndrome. Sleep Med. 2015;19:50\u20136.","journal-title":"Sleep Med."},{"issue":"9","key":"584_CR27","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2165\/11634870-000000000-00000","volume":"26","author":"SA VanMeter","year":"2012","unstructured":"VanMeter SA, Kavanagh ST, Warren S, et al. Dose response of gabapentin enacarbil versus placebo in subjects with moderate-to-severe primary restless legs syndrome: an integrated analysis of three 12-week studies. CNS Drugs. 2012;26(9):773\u201380.","journal-title":"CNS Drugs."},{"key":"584_CR28","author":"WG Ondo","year":"2015","unstructured":"Ondo WG, Hermanowicz N, Garcia Borreguero D, et al. Effect of prior exposure to dopamine agonists on treatment with gabapentin enacarbil in adults with moderate-to-severe primary restless legs syndrome: pooled analyses from 3 randomized trials. J Clin Mov Disord. 2015. doi: 10.1186\/s40734-015-0018-3 .","journal-title":"J Clin Mov Disord."},{"key":"584_CR29","doi-asserted-by":"crossref","unstructured":"Hermanowicz N, Buchfuhrer M, Wynn D, et al. The effect of gabapentin enacarbil (GEn) on pain outcomes in adults with moderate-to-severe and severe primary restless legs syndrome (RLS): pooled analyses from 3 randomized controlled trials [abstract no. P7.294 plus poster]. In: 67th Annual Meeting of the American Academy of Neurology; 2015.","DOI":"10.1212\/WNL.84.14_supplement.P7.294"},{"key":"584_CR30","author":"N Hermanowicz","year":"2016","unstructured":"Hermanowicz N, Ellenbogen A, Irving G, et al. The effect of gabapentin enacarbil on pain associated with moderate-to-severe primary restless legs syndrome in adults: pooled analyses from three randomized controlled trials. CNS Drugs. 2016. doi: 10.1007\/s40263-016-0333-8 .","journal-title":"CNS Drugs."},{"key":"584_CR31","unstructured":"Ahmed M, Hays R, Poceta J, et al. The effect of gabapentin enacarbil on individual items of the international restless legs scale and post-sleep questionnaire in patients with moderate-to-severe primary restless legs syndrome: pooled analyses from 3 randomized trials [abstract no. 0634]. Sleep. 2014;37(abstract supplement):A221."},{"issue":"3","key":"584_CR32","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3109\/07853890.2015.1025825","volume":"47","author":"RK Bogan","year":"2015","unstructured":"Bogan RK, Lee DO, Buchfuhrer MJ, et al. Treatment response to sleep, pain, and mood disturbance and their correlation with sleep disturbance in adult patients with moderate-to-severe primary restless legs syndrome: pooled analyses from 3 trials of gabapentin enacarbil. Ann Med. 2015;47(3):269\u201377.","journal-title":"Ann Med."},{"key":"584_CR33","author":"AY Avidan","year":"2016","unstructured":"Avidan AY, Lee D, Park M, et al. The effect of gabapentin enacarbil on quality of life and mood outcomes in a pooled population of adult patients with moderate-to-severe primary restless legs syndrome. CNS Drugs. 2016. doi: 10.1007\/s40263-016-0329-4 .","journal-title":"CNS Drugs."},{"key":"584_CR34","doi-asserted-by":"crossref","unstructured":"Avidan A, Isaacson S, Jaros M, et al. The effect of gabapentin enacarbil (GEn) on quality-of-life (QoL) outcomes in adult patients with moderate-to-severe and severe primary restless legs syndrome (RLS): pooled analyses from two 12-week trials [abstract no. P7.299]. Neurology. 2015;84(14 Suppl).","DOI":"10.1212\/WNL.84.14_supplement.P7.299"},{"issue":"1","key":"584_CR35","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/WNF.0b013e3182087d48","volume":"34","author":"AL Ellenbogen","year":"2011","unstructured":"Ellenbogen AL, Thein SG, Winslow DH, et al. A 52-week study of gabapentin enacarbil in restless legs syndrome. Clin Neuropharmacol. 2011;34(1):8\u201316.","journal-title":"Clin Neuropharmacol."},{"issue":"2","key":"584_CR36","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.pnpbp.2011.10.009","volume":"36","author":"Y Inoue","year":"2012","unstructured":"Inoue Y, Uchimura N, Kuroda K, et al. Long-term efficacy and safety of gabapentin enacarbil in Japanese restless legs syndrome patients. Prog Neuropsychopharmacol Biol Psychiatry. 2012;36(2):251\u20137.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"issue":"6","key":"584_CR37","doi-asserted-by":"crossref","first-page":"512","DOI":"10.4065\/mcp.2009.0700","volume":"85","author":"RK Bogan","year":"2010","unstructured":"Bogan RK, Cramer Bornemann MA, Kushida CA, et al. Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study. Mayo Clin Proc. 2010;85(6):512\u201321.","journal-title":"Mayo Clin Proc."},{"key":"584_CR38","unstructured":"US FDA. Horizant (gabapentin enacarbil) medial review. 2011. https:\/\/www.fda.gov . Accessed 26 Apr 2016."},{"issue":"2","key":"584_CR39","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/pds.2266","volume":"21","author":"MC Irizarry","year":"2012","unstructured":"Irizarry MC, Webb DJ, Boudiaf N, et al. Risk of cancer in patients exposed to gabapentin in two electronic medical record systems. Pharmacoepidemiol Drug Saf. 2012;21(2):214\u201325.","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"584_CR40","unstructured":"Pharmaceuticals and Medical Devices Agency. Regnite\u00ae tablets: Japanese prescribing information (in Japanese). 2015. http:\/\/www.pmda.go.jp\/english\/ . Accessed 26 Apr 2016."},{"issue":"8","key":"584_CR41","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.5665\/sleep.1986","volume":"35","author":"RN Aurora","year":"2012","unstructured":"Aurora RN, Kristo DA, Bista SR, et al. The treatment of restless legs syndrome and periodic limb movement disorder in adults-an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine clinical practice guideline. Sleep. 2012;35(8):1039\u201362.","journal-title":"Sleep."},{"issue":"8","key":"584_CR42","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.5665\/sleep.1986","volume":"35","author":"RN Aurora","year":"2012","unstructured":"Aurora RN, Kristo DA, Bista SR, et al. Update to the AASM clinical practice guideline: \u201cThe treatment of restless legs syndrome and periodic limb movement disorder in adults-an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses\u201d. Sleep. 2012;35(8):1037.","journal-title":"Sleep."},{"issue":"11","key":"584_CR43","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/j.1468-1331.2012.03853.x","volume":"19","author":"D Garcia-Borreguero","year":"2012","unstructured":"Garcia-Borreguero D, Ferini-Strambi L, Kohnen R, et al. European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. Eur J Neurol. 2012;19(11):1385\u201396.","journal-title":"Eur J Neurol."},{"issue":"7","key":"584_CR44","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.sleep.2013.05.016","volume":"14","author":"D Garcia-Borreguero","year":"2013","unstructured":"Garcia-Borreguero D, Kohnen R, Silber MH, et al. The long-term treatment of restless legs syndrome\/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Med. 2013;14(7):675\u201384.","journal-title":"Sleep Med."},{"issue":"11","key":"584_CR45","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1185\/03007995.2014.946124","volume":"30","author":"Y Sun","year":"2014","unstructured":"Sun Y, van Valkenhoef G, Morel T. A mixed treatment comparison of gabapentin enacarbil, pramipexole, ropinirole and rotigotine in moderate-to-severe restless legs syndrome. Curr Med Res Opin. 2014;30(11):2267\u201378.","journal-title":"Curr Med Res Opin."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0584-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-016-0584-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0584-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T06:08:09Z","timestamp":1718518089000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-016-0584-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["584"],"URL":"https:\/\/doi.org\/10.1007\/s40265-016-0584-1","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5]]}}}